Merz Therapeutics Strengthens European Footprint with Launch of New Affiliate in Poland Merz Therapeutics GmbH, a globally recognized leader in neurology-focused specialty pharmaceuticals, has officially announced the opening of its new affiliate in Warsaw, Poland. This strategic expansion marks a…
Kairos Pharma to Present Promising Phase 2 Prostate Cancer Data Highlighting Carotuximab’s Potential to Overcome Hormone Therapy Resistance at ESMO 2025 Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on developing novel cancer therapeutics that address treatment…
Allurion Publishes Landmark Peer-Reviewed Study Demonstrating Over 20% Total Body Weight Loss With Consecutive Use of Its Smart Capsule Allurion Technologies, Inc. (NYSE: ALUR), a global leader in developing innovative, non-surgical weight-loss solutions, announced a major milestone in the field…
Bimiralisib Topical PI3K/mTOR Inhibitor Demonstrates Up to 92% Clearance and Excellent Tolerability in Phase 2 Actinic Keratosis Trial Torqur AG, a clinical-stage biopharmaceutical company and a subsidiary of the Swiss Rockets AG incubator, has announced highly encouraging results from its…
Presto Dental Opens Flagship Multi-Specialty Practice in Bridgeport, Expanding Abra Health Group’s Connecticut Presence Presto Dental, a new and innovative dental brand affiliated with the Abra Health Group, has officially opened its first flagship location in Bridgeport, Connecticut. This milestone…
ENHERTU® Demonstrates Significant Superiority Over T-DM1 in DESTINY-Breast05 Phase 3 Trial for High-Risk HER2 Positive Early Breast Cancer Patients Positive topline results from the planned interim analysis of the DESTINY-Breast05 phase 3 clinical trial have reinforced the potential of ENHERTU®…
Lundbeck Partners with Migraine Community to Transform Care and Improve Lives Despite being recognized as one of the leading causes of disability worldwide, migraine remains widely misunderstood, and the profound impact it has on individuals’ daily lives is often underestimated…
Kardigan Accelerates Development of Transformative Cardiovascular Medicines Across Three Critical Disease Areas Kardigan, a pioneering heart health company dedicated to modernizing cardiovascular drug development, today unveiled the three late-stage clinical programs that anchor its rapidly advancing pipeline. These programs represent…
New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies Novartis today announced new data from two Kesimpta® (ofatumumab) studies in relapsing multiple sclerosis (RMS) that will be presented at the European Committee…
Acadia Scraps Prader-Willi Drug After Late-Stage Failure Acadia Pharmaceuticals was testing the drug, an intranasal formulation of the oxytocin analogue carbetocin, for its potential to ease hyperphagia in the rare neurological condition. Acadia Pharmaceuticals’ investigational treatment for hyperphagia in Prader-Willi…
Talent Acquisition Leaders Reframe Recruiting, Focus On Internal Mobility Talent acquisition leaders at leading pharma and biotech organizations are leveraging technologies, including automation, to develop internal talent marketplaces and systems that support upskilling and reskilling their workforce. BioSpace spoke to leaders at Pfizer and…
Embracing Communities of Innovation: Massachusetts Our strategy to transform patients’ lives has always centered on building state-of-the-art research centers within communities that spark innovation. Massachusetts stands as a global hub for life sciences, home to some of the brightest minds…
